Rilonacept

Rilonacept, also known as IL-1 Trap (marketed by Regeneron Pharmaceuticals under the trade name Arcalyst), is an interleukin 1 inhibitor.[1]

Rilonacept
Clinical data
AHFS/Drugs.comMonograph
License data
Routes of
administration		Subcutaneous
ATC code
Legal status
Legal status
Identifiers
CAS Number
ChemSpider
  • none
UNII
ChEMBL
 NY (what is this?)  (verify)

Rilonacept is a dimeric fusion protein consisting of the ligand-binding domains of the extracellular portions of the human interleukin-1 receptor component (IL-1R1) and IL-1 receptor accessory protein (IL-1RAcP) linked in-line to the fragment-crystallizable portion (Fc region) of human IgG1 that binds and neutralizes IL-1.[2]

Rilonacept was given an "orphan drug" status by the United States Food and Drug Administration and is used for the treatment of cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome, Muckle–Wells syndrome and neonatal onset multisystem inflammatory disease (It is not approved in the U.S. on this indication).[3]

On May 8th, 2012 an FDA Advisory Panel voted 11–0 against the approval of rilonacept for the treatment of gout, stating that the benefits did not outweigh the risks associated with the drug.[4]

References
  1. Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, et al. (October 2009). "The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study". Annals of the Rheumatic Diseases. 68 (10): 1613–7. doi:10.1136/ard.2009.108936. PMC 2732898. PMID 19635719.
  2. "Molecule of the month. Rilonacept". Drug News & Perspectives. 21 (4): 232. May 2008. PMID 18560622.
  3. "Arcalyst FDA Approval History - Drugs.com". Archived from the original on 2012-05-16. Retrieved 2012-05-08.
  4. "Medical News: FDA Panel Nixes Gout Drug - in Rheumatology, General Rheumatology from MedPage Today". Archived from the original on 2012-05-21. Retrieved 2012-05-08.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.